Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1991-11-1
pubmed:abstractText
Antigen-presenting cells (APC) transfected with a construct encoding the hen egg-white lysozyme (HEL) amino acid sequence 1-80 constitutively present HEL peptides complexed to major histocompatibility complex (MHC) class II molecules to specific T cell hybridomas, indicating that endogenous cellular antigens can be efficiently presented to class II-restricted T cells. Here we show that exogenous peptide competitors added to HEL-transfected APC can inhibit the presentation of endogenous HEL peptides to class II-restricted T cells. The inhibition is specific for the class II molecule binding the competitor peptide, and it affects to the same extent presentation of exogenous or endogenous HEL peptides. These results, demonstrating that an exogenous competitor can inhibit class II-restricted T cell activation induced by endogenous as well as exogenous antigen, suggest lack of strict compartmentalization between endogenous and exogenous pathways of antigen presentation. Since autoreactive T cells may recognize endogenous, as well as exogenous antigens, the results have implications for the treatment of autoimmune diseases by MHC blockade.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-1701780, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-1707537, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-1847667, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-1970351, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-2156628, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-2456369, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-2462005, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-2471972, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-2513490, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-2784508, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-2961215, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-2999796, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-3258651, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-3459185, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-3485173, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-3489186, http://linkedlifedata.com/resource/pubmed/commentcorrection/1919443-59974
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0022-1007
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
174
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
945-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells.
pubmed:affiliation
Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland.
pubmed:publicationType
Journal Article